Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. (Q51312581)

From Wikidata

Jump to navigation Jump to search

scientific article published on 10 December 2014

Language	Label	Description	Also known as
English	Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.	scientific article published on 10 December 2014

Statements

scholarly article

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. (English)

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

P D Home

1

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

P Shamanna

2

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

M Stewart

3

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

F Yang

4

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

M Miller

5

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

C Perry

6

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

M C Carr

7

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

publication date

10 December 2014

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

17

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

179-187

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

2

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

Report of the committee on the classification and diagnostic criteria of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Standards of medical care in diabetes--2010.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

AACE comprehensive diabetes management algorithm 2013.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Standards of medical care in diabetes--2014

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinic

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Identifiers

10.1111/DOM.12414

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51312581&oldid=1254550353"